

## Transparency notification Wellington

Brussels (Belgium), 18 May 2022 – 18:00 (CEST) – Regulated information

### 1. Summary of the notification

Pursuant to Article 14 of the law of 2 May 2007 on the disclosure of large shareholdings, UCB SA/NV announces that it has received a transparency notification from Wellington Management Group LLP (having its registered offices at 280 Congress Street, Boston, MA 02210, USA) on 16 May 2022.

Wellington Management Group LLP has notified that, following an acquisition of UCB shares with voting rights by its affiliates, its shareholding in UCB SA/NV has increased and it has crossed the 7.5% threshold, on 13 May 2022.

On 13 May 2022, Wellington Management Group LLP (taking into account the holding of its affiliates) owned 15 166 845 UCB shares with voting rights, representing 7.80% of the total number of shares issued by the company (194 505 658), versus 7.46% (14 516 633 UCB shares) in the previous notification dated 2 September 2021.

### 2. Content of the notification

- **Reason for the notification:** Acquisition or disposal of voting securities or voting rights.
- **Notification by:** A parent undertaking or a controlling person.
- **Persons subject to the notification requirement:**

Name	Address (for legal entities)
Wellington Management Group LLP	280 Congress Street, Boston, MA, 02210

- **Date on which the threshold is crossed:** 13 May 2022.
- **Threshold crossed (in %):** 7.5%.
- **Denominator:** 194 505 658.

- **Notified details:**

A) Voting rights	Previous notification	After the transaction			
	# of voting rights	# of voting rights		% of voting rights	
Holders of voting rights		Linked to securities	Not linked to the securities	Linked to securities	Not linked to the securities
Wellington Management Group LLP	0	0		0,00%	
Wellington Management International Ltd	1.933.226	1.214.415		0,62%	
Wellington Management Company LLP	12.583.407	13.952.342		7,17%	
Wellington Management Europe GmbH	0	88		0,00%	
Subtotal	14.516.633	15.166.845		7,80%	
<b>TOTAL</b>		<b>15.166.845</b>	<b>0</b>	<b>7,80%</b>	<b>0,00%</b>

  

B) Equivalent financial instruments	After the transaction					
	Type of financial instrument	Expiration date	Exercise period or date	# of voting rights that may be acquired if the instrument is exercised	% of voting rights	Settlement
<b>TOTAL</b>				<b>0</b>	<b>0,00%</b>	
<b>TOTAL (A &amp; B)</b>				<b># of voting rights</b>	<b>% of voting rights</b>	
				<b>CALCULATE</b>	<b>15.166.845</b>	<b>7,80%</b>

- **Chain of controlled undertakings through which the holding is effectively held:**

Wellington Management Company LLP is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

Wellington Management International Ltd and Wellington Management Europe GmbH are direct controlled undertakings of Wellington Management Global Holdings, Ltd. which, in turn, is a direct controlled undertaking of Wellington Investment Advisors Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Group Holdings LLP which, in turn, is a direct controlled undertaking of Wellington Management Group LLP.

The shares are registered in the names of the Accounts or nominees according to their respective holdings.

- **Additional information:** Wellington Management Company LLP, Wellington Management International Ltd and Wellington Management Europe GmbH are investment management

companies and can exercise the voting rights at their discretion in the absence of specific instructions from the beneficial owners of the shares.

### **3. Further information**

This press release and the detailed transparency notification are available on UCB SA/NV's website via the following [link](#).

An updated overview of the UCB SA/NV large shareholdings will be available on UCB SA/NV's website via the following [link](#).

---

#### **For further information, contact UCB:**

##### **Investor Relations**

Antje Witte  
T +32 2 559 94 14  
[antje.witte@ucb.com](mailto:antje.witte@ucb.com)

##### **Corporate Communications**

Laurent Schots  
T+32 2 559 92 64  
[laurent.schots@ucb.com](mailto:laurent.schots@ucb.com)

##### **About UCB**

UCB, Brussels, Belgium ([www.ucb.com](http://www.ucb.com)) is a global biopharmaceutical company focused on the discovery and development of innovative medicines and solutions to transform the lives of people living with severe diseases of the immune system or of the central nervous system. With approximately 8 600 people in nearly 40 countries, the company generated revenue of € 5.8 billion in 2021. UCB is listed on Euronext Brussels (symbol: UCB). Follow us on Twitter: @UCB\_news